Cargando…
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
AIMS: Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients’ quality of life. The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospit...
Autores principales: | Torp-Pedersen, Christian, Crijns, Harry J.G.M., Gaudin, Christophe, Page, Richard L., Connolly, Stuart J., Hohnloser, Stefan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148817/ https://www.ncbi.nlm.nih.gov/pubmed/21576129 http://dx.doi.org/10.1093/europace/eur102 |
Ejemplares similares
-
Dronedarone in patients with congestive heart failure: insights from ATHENA
por: Hohnloser, Stefan H., et al.
Publicado: (2010) -
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial
por: Pisters, Ron, et al.
Publicado: (2014) -
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020) -
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study
por: Vamos, Mate, et al.
Publicado: (2019) -
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)